Jan Borysowski

Dr. Jan Borysowski


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2006 in Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
JBJan Borysowski
Jan Borysowski
BWBeata Weber-Dąbrowska
Beata Weber-Dąbrowska
AGAndrzej Górski
Andrzej Górski
Endolysins are double-stranded DNA bacteriophage-encoded peptidoglycan hydrolases produced in phage-infected bacterial cells toward the end of the lytic cycle. They reach the peptidoglycan through membrane lesions formed by holins and cleave it, thus, inducing lysis of the bacterial cell and enabling progeny virions to be released. Endolysins are also capable of degrading peptidoglycan when applied externally (as purified recombinant proteins) to the bacterial cell wall, which also results in a rapid lysis of the bacterial cell. The unique ability of endolysins to rapidly cleave peptidoglycan in a generally species-specific manner renders them promising potential antibacterial agents. Originally developed with a view to killing bacteria colonizing mucous membranes (with the first report published in 2001), endolysins also hold promise for the treatment of systemic infections. As potential antibacterials, endolysins possess several important features, for instance, a novel mode of action, a narrow antibacterial spectrum, activity against bacteria regardless of their antibiotic sensitivity, and a low probability of developing resistance. However, there is only one report directly comparing the activity of an endolysin with that of an antibiotic, and no general conclusions can be drawn regarding whether lysins are more effective than traditional antibiotics. The results of the first preclinical studies indicate that the most apparent potential problems associated with endolysin therapy (e.g., their immunogenicity, the release of proinflammatory components during bacteriolysis, or the development of resistance), in fact, may not seriously hinder their use. However, all data regarding the safety and therapeutic effectiveness of endolysins obtained from preclinical studies must be ultimately verified by clinical trials. This review discusses the prophylactic and therapeutic applications of endolysins, especially with respect to their potential use in human medicine. Additionally, we outline current knowledge regarding the structure and natural function of the enzymes in phage biology, including the most recent findings.

28 May 2018 in Viruses
Verified
Journal Article
Open access
PDF file
AGAndrzej Górski
Andrzej Górski
RMRyszard Międzybrodzki
Ryszard Międzybrodzki
MLMalgorzata Lobocka
Malgorzata Lobocka
ARAleksandra Głowacka- Rutkowska
Aleksandra Głowacka- Rutkowska
ABAgnieszka Bednarek
Agnieszka Bednarek
JSJacques Scheres
Jacques Scheres
In this article we explain how current events in the field of phage therapy may positively influence its future development. We discuss the shift in position of the authorities, academia, media, non-governmental organizations, regulatory agencies, patients, and doctors which could enable further advances in the research and application of the therapy. In addition, we discuss methods to obtain optimal phage preparations and suggest the potential of novel applications of phage therapy extending beyond its anti-bacterial action.

19 November 2020 in Antibiotics
Verified
Journal Article
Open access
PDF file
AGAndrzej Górski
Andrzej Górski
JBJan Borysowski
Jan Borysowski
RMRyszard Międzybrodzki
Ryszard Międzybrodzki
While phage therapy carried out as compassionate use (experimental therapy) has recently flourished, providing numerous case reports of supposedly healed patients, clinical trials aiming to formally prove their value in accord with current regulatory requirements have failed. In light of the current issue of increasing antibiotic resistance, the need for a final say regarding the place of phage therapy in modern medicine is evident. We analyze the possible factors that may favor success or lead to the failure of phage therapy: quality of phage preparations, their titer and dosage, as well as external factors that could also contribute to the outcome of phage therapy. Hopefully, better control of these factors may eventually bring about long-awaited positive results.

1 September 2008 in International Journal of Infectious Diseases
Verified
Journal Article
Closed access
JBJan Borysowski
Jan Borysowski
AGAndrzej Górski
Andrzej Górski

16 December 2020 in Microorganisms
Verified
Journal Article
Open access
PDF file
MŁMarzanna Łusiak-Szelachowska
Marzanna Łusiak-Szelachowska
BWBeata Weber-Dąbrowska
Beata Weber-Dąbrowska
MŻMaciej Żaczek
Maciej Żaczek
JBJan Borysowski
Jan Borysowski
AGAndrzej Górski
Andrzej Górski
The presence of bacteriophages (phages) in the human body may impact bacterial microbiota and modulate immunity. The role of phages in human microbiome studies and diseases is poorly understood. However, the correlation between a greater abundance of phages in the gut in ulcerative colitis and diabetes has been suggested. Furthermore, most phages found at different sites in the human body are temperate, so their therapeutic effects and their potential beneficial effects remain unclear. Hence, far, no correlation has been observed between the presence of widespread crAssphage in the human population and human health and diseases. Here, we emphasize the beneficial effects of phage transfer in fecal microbiota transplantation (FMT) in Clostridioides difficile infection. The safety of phage use in gastrointestinal disorders has been demonstrated in clinical studies. The significance of phages in the FMT as well as in gastrointestinal disorders remains to be established. An explanation of the multifaceted role of endogenous phages for the development of phage therapy is required.

1 January 2009 in BMC Microbiology
Verified
Journal Article
Open access
PDF file
MZMichał Zimecki
Michał Zimecki
JAJolanta Artym
Jolanta Artym
MKMaja Kocięba
Maja Kocięba
BWBeata Weber-Dąbrowska
Beata Weber-Dąbrowska
JBJan Borysowski
Jan Borysowski
AGAndrzej Górski
Andrzej Górski
Bacteriophages can be successfully applied to treat infections caused by antibiotic-resistant bacteria. Until now no attempts have been undertaken to treat infections in immunosuppressed patients with phages. In this work we investigated the prophylactic efficacy of specific bacteriophages in CBA mice treated with cyclophosphamide (CP) and infected with Staphylococcus aureus.